论文部分内容阅读
大肠癌是常见的实体瘤之一,也是五大死亡率最高的癌肿之一。美国每年结、直肠癌死亡的患者高达55300人,中国为53200人。结、直肠癌的发病率在逐年上升,尤其在发达国家。尽管70％—80％的结、直肠癌的病人从手术大体标本看为根治性切除,但其中一半的病人将会复发并最终死于本病。因此,大肠癌的化疗显得尤为重要。1957年5月5—氟脲嘧啶(5-Fu)问世以来,人们开始对大肠癌进行化疗,近10年来才明确了5-Fu在大肠癌化疗中的地位,人们正在通过大量的临床试验来确定辅助
Colorectal cancer is one of the common solid tumors and one of the top five cancer cancers. Each year in the United States, there are 55,300 deaths from colorectal cancer and 53,200 from China. The incidence of colorectal cancer is increasing year by year, especially in developed countries. Although 70% to 80% of patients with colorectal cancer who undergo radical resection of the gross specimen of the surgery, half of these patients will relapse and eventually die of the disease. Therefore, the chemotherapy of colorectal cancer is particularly important. Since the advent of 5-fluorouracil (5-Fu) in May 1957, chemotherapy for colorectal cancer has been initiated and the status of 5-Fu in the treatment of colorectal cancer has been clarified in the recent 10 years. People are going through a large number of clinical trials Confirm assistance